Inhibrx Biosciences, Inc. INBX
Inhibrx Biosciences, Inc. (Nasdaq: INBX) is an oncology drug developer. Its lead program, ozekibart (INBRX-109), is in Phase 3 for conventional chondrosarcoma (BLA); also colorectal cancer, Ewing sarcoma. Its next catalyst on record is ozekibart: FDA meeting on first-line registrational CRC trial and potential accelerated pathway in 4L CRC (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ozekibart — FDA meeting on first-line registrational CRC trial and potential accelerated pathway in 4L CRC (Q4 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ozekibart (INBRX-109) | conventional chondrosarcoma (BLA accepted for filing Jun 2026) | antibody | Phase 3 |
| ozekibart (INBRX-109) | colorectal cancer (Phase 1/2 with FOLFIRI; additional Phase 1 cohorts) | antibody | Phase 2 |
| ozekibart (INBRX-109) | Ewing sarcoma (Phase 1/2 with IRI/TMZ) | antibody | Phase 2 |
| INBRX-106 | first-line PD-L1+ head and neck squamous cell carcinoma with pembrolizumab (HexAgon Phase 2/3; Phase 3 portion planned) | antibody | Phase 2 |
Recent results and decisions
- Sep 8, 2026positive Randomized Phase 2 primary endpoint: cORR 48.3% vs 26.5% for pembrolizumab alone; interim median PFS 9.6 vs 4.9 months; HPV+ cORR 80.0% vs 33.3%.
The primary endpoint analysis, which had a data cutoff of August 19, 2026, demonstrated a confirmed objective response rate (cORR) of 48.3% for INBRX-106 plus pembrolizumab compared with 26.5% for pembrolizumab alone.
Filing - Jun 15, 2026accepted FDA accepted BLA for filing with no filing review issues; PDUFA goal date April 14, 2027.
The FDA has not identified any filing review issues at this time and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027.
Filing - Apr 21, 2026positive Updated interim Phase 1/2 CRC data: ORR 20% (45 evaluable) vs 1-6% historical SOC, median PFS 5.5 months, DCR 87%.
As of April 10, 2026, the cutoff date, the CRC cohort continued to demonstrate a compelling signal of activity in a heavily pretreated patient population.
Filing
5 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.